Aaron Mansfield, MD
- Undergraduate degree from Stanford University
- Medical degree from University of California
- Residency in Internal Medicine at Mayo Clinic
- Currently a clinician investigator and fellow in hematology/oncology at the Mayo Clinic.
Dr. Mansfield is from Southern California.
Dr. Mansfield is a medical oncologist with a focus on thoracic malignancies and early therapeutics. His initial research focused on regional immunity in both melanoma and breast cancer. He was the first to describe the negative prognostic significance of PD-L1 expression in mesothelioma and led the discovery that chromosomal rearrangements have neo-antigenic potential. He is the principal investigator of many clinical trials and translational projects evaluating the ability of blood-based biomarkers to predict responses to immunotherapy. He also helped lead accrual to the recent clinical trial that changed the practice of frontline therapy for patients with extensive stage small cell lung cancer.